Uterine Neoplasms Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewAdenocarcinoma of the endometrium is the most common malignancy in the female genital tract in the United States. An estimated 40,100 new diagnoses of uterine cancer and 7470 deaths from this disease will occur in 2008.1 Uterine sarcomas are uncommon and account for approximately 1 in 12 of all uterine cancers.2 These guidelines describe epithelial carcinomas and uterine sarcomas; each of these major categories contains specific histologic groups that require different management (see page 500).By definition, these guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among panel members during the process of developing these guidelines.For patients with suspected uterine neoplasms, initial preoperative evaluation includes a history and physical examination, endometrial biopsy, chest radiograph, a CBC,...
If the inline PDF is not rendering correctly, you can download the PDF file here.
UedaSM, KappDS, CheungMK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol2008;198:218.e1–6.
UedaSMKappDSCheungMK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol2008;198:218.e1–6.
)| false
DukJM, AaldersJG, FleurenGJ. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol1989;73:661–668.
DukJMAaldersJGFleurenGJ. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol1989;73:661–668.
)| false
PatsnerB, OrrJWJr, MannWJJr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol1990;162:427–429.
PatsnerBOrrJWJrMannWJJr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol1990;162:427–429.
)| false
RosePG, SommersRM, RealeFR. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol1994;84:12–16.
RosePGSommersRMRealeFR. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol1994;84:12–16.
)| false
GimpelsonRJ, RappoldHO. A comparative study between panoramic hysterectomy with directed biopsies and dilatation and curettage: a review of 276 cases. Am J Obstet Gynecol1998;158:489–492.
GimpelsonRJRappoldHO. A comparative study between panoramic hysterectomy with directed biopsies and dilatation and curettage: a review of 276 cases. Am J Obstet Gynecol1998;158:489–492.
)| false
CowlesTA, MagrinaJF, MastersonBJ. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol1985;66:413–416.
CowlesTAMagrinaJFMastersonBJ. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol1985;66:413–416.
)| false
BenedetJL, BenderH, JonesHIII. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet2000;70:209–262.
BenedetJLBenderHJonesHIII. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet2000;70:209–262.
)| false
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol2005;106:413–425.
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol2005;106:413–425.
)| false
MarianiA, DowdySC, ClibyWA. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol2008;109:11–18.
MarianiADowdySCClibyWA. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol2008;109:11–18.
)| false
ASTEC study groupKitchenerH, SwartAM. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet2009;373:125–136.
ASTEC study groupKitchenerHSwartAM. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet2009;373:125–136.
)| false
CreasmanWT, OdicinoF, MaisonneuveP. Carcinoma of the corpus uteri. FIGO 6th annual report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet2006;95(Suppl 1):S105–143.
CreasmanWTOdicinoFMaisonneuveP. Carcinoma of the corpus uteri. FIGO 6th annual report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet2006;95(Suppl 1):S105–143.
)| false
FishmanDA, RobertsKB, ChambersJT. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol1996;61:189–196.
FishmanDARobertsKBChambersJT. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol1996;61:189–196.
)| false
KilgoreLC, PartridgeEE, AlvarezRD. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol1995;56:29–33.
KilgoreLCPartridgeEEAlvarezRD. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol1995;56:29–33.
)| false
CreutzbergCL, van PuttenWL, KoperPC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet2000;355:1404–1411.
CreutzbergCLvan PuttenWLKoperPC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet2000;355:1404–1411.
)| false
AaldersJ, AbelerV, KolstadP. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol1980;56:419–427.
AaldersJAbelerVKolstadP. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol1980;56:419–427.
)| false
KeysHM, RobertsJA, BrunettoVL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2004;92:744–751.
KeysHMRobertsJABrunettoVL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2004;92:744–751.
)| false
CreutzbergCL, van PuttenWL, Warlam-RodenhuisCC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol2004;22:1234–1241.
CreutzbergCLvan PuttenWLWarlam-RodenhuisCC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol2004;22:1234–1241.
)| false
ScholtenAN, van PuttenWL, BeermanH. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys2005;63:834–838.
ScholtenANvan PuttenWLBeermanH. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys2005;63:834–838.
)| false
ASTEC/EN.5 Study GroupBlakeP, SwartAM. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet2009;373:137–146.
ASTEC/EN.5 Study GroupBlakePSwartAM. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet2009;373:137–146.
)| false
LeeCM, SzaboA, ShrieveDC. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA2006;295:389–397.
LeeCMSzaboAShrieveDC. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA2006;295:389–397.
)| false
JohnsonN, CornesP. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG2007;114:1313–1320.
JohnsonNCornesP. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG2007;114:1313–1320.
)| false
HogbergT, RosenbergP, KristensenG. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol2007;25:Abstract 5503.
HogbergTRosenbergPKristensenG. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol2007;25:Abstract 5503.
)| false
MorrowCP, BundyBN, KurmanRJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol1991;40:55–65.
MorrowCPBundyBNKurmanRJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol1991;40:55–65.
)| false
KadarN, HomesleyHD, MalfetanoJH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol1992;46:145–149.
KadarNHomesleyHDMalfetanoJH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol1992;46:145–149.
)| false
Owen Mumford. Best Practice Guidelines on the Use of Vaginal Dilators in Women Receiving Pelvic radiotherapy. Available at: http://www.owenmumford.com/en/download.asp?id=59. Accessed March 25, 2009.
Owen Mumford. Best Practice Guidelines on the Use of Vaginal Dilators in Women Receiving Pelvic radiotherapy. Available at: http://www.owenmumford.com/en/download.asp?id=59. Accessed March 25, 2009.
)| false
WalkerJL, PiedmonteM, SpirtosN. Surgical staging of uterine cancer: randomized phase III trial of laparoscopy vs laparotomy—a Gynecologic Oncology Group study (GOG): preliminary results [Abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 5010.
WalkerJLPiedmonteMSpirtosN. Surgical staging of uterine cancer: randomized phase III trial of laparoscopy vs laparotomy—a Gynecologic Oncology Group study (GOG): preliminary results [Abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 5010.
)| false
MalurS, PossoverM, MichelsW, SchneiderA. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer—a prospective randomized trial. Gynecol Oncol2001;80:239–244.
MalurSPossoverMMichelsWSchneiderA. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer—a prospective randomized trial. Gynecol Oncol2001;80:239–244.
)| false
ObermairA, ManolitsasTP, LeungY. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecol Oncol2004;92:789–793.
ObermairAManolitsasTPLeungY. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecol Oncol2004;92:789–793.
)| false
BoggessJF, GehrigPA, CantrellL. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol2008;199:360.e1–9.
BoggessJFGehrigPACantrellL. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol2008;199:360.e1–9.
)| false
ChadhaM, NanavatiPJ, LiuP. Patterns of failure in endometrial carcinoma stage IB, grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol1999;75:103–107.
ChadhaMNanavatiPJLiuP. Patterns of failure in endometrial carcinoma stage IB, grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol1999;75:103–107.
)| false
ChiDS, BarakatRR, PalayekarMJ. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer2008;18:269–273.
ChiDSBarakatRRPalayekarMJ. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer2008;18:269–273.
)| false
GretzHFIII, EconomosK, HusainA. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol1996;61:409–415.
GretzHFIIIEconomosKHusainA. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol1996;61:409–415.
)| false
SusumuN, SagaeS, UdagawaY. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol2008;108:226–233.
SusumuNSagaeSUdagawaY. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol2008;108:226–233.
)| false
GreerBE, HambergerAD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol1983;16:365–373.
GreerBEHambergerAD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol1983;16:365–373.
)| false
RandallME, FiliaciVL, MussH. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol2006;24:36–44.
RandallMEFiliaciVLMussH. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol2006;24:36–44.
)| false
HomesleyHD, FiliaciV, GibbonsSK. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract]. 39th Annual Meeting of the Society of Gynecologic Oncologists; Tampa, FL; March 9, 2008. Abstract #1. Gynecol Oncol2008;108:S2.
HomesleyHDFiliaciVGibbonsSK. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract]. 39th Annual Meeting of the Society of Gynecologic Oncologists; Tampa, FL; March 9, 2008. Abstract #1. Gynecol Oncol2008;108:S2.
)| false
GotliebWH, BeinerME, ShalmonB. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol2003;102:718–725.
GotliebWHBeinerMEShalmonB. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol2003;102:718–725.
)| false
RamirezPT, FrumovitzM, BodurkaDC. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol2004;95:133–138.
RamirezPTFrumovitzMBodurkaDC. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol2004;95:133–138.
)| false
PodczaskiE, KaminskiP, GurskiK. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol1992;47:323–327.
PodczaskiEKaminskiPGurskiK. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol1992;47:323–327.
)| false
KauppilaA. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol1989;28:561–566.
KauppilaA. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol1989;28:561–566.
)| false
ThigpenJT, BradyMF, AlvarezRD. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol1999;17:1736–1744.
ThigpenJTBradyMFAlvarezRD. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol1999;17:1736–1744.
)| false
ThigpenT, BradyMF, HomesleyHD. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2001;19:364–367.
ThigpenTBradyMFHomesleyHD. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2001;19:364–367.
)| false
FlemingGF, BrunettoVL, CellaD. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2004;22:2159–2166.
FlemingGFBrunettoVLCellaD. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2004;22:2159–2166.
)| false
ReddySP, KudelkaAP, Gonzalez de LeonC. Tumors of the uterine corpus. In: PazdurR, ed. Medical Oncology: A Comprehensive Review. Huntington: PRR; 1996:407–416.
ReddySPKudelkaAPGonzalez de LeonC. Tumors of the uterine corpus. In: PazdurR, ed. Medical Oncology: A Comprehensive Review. Huntington: PRR; 1996:407–416.
)| false
SovakMA, DupontJ, HensleyML. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer2007;17:197–203.
SovakMADupontJHensleyML. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer2007;17:197–203.
)| false
SecordAA, HavrileskyLJ, CarneyME. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol2007;12:31–36.
SecordAAHavrileskyLJCarneyME. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol2007;12:31–36.
)| false
ThomasMB, MarianiA, ClibyWA. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol2007;107:186–189.
ThomasMBMarianiAClibyWA. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol2007;107:186–189.
)| false
GoldbergH, MillerRC, Abdah-BortnyakR. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol2008;108:298–305.
GoldbergHMillerRCAbdah-BortnyakR. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol2008;108:298–305.
)| false
HamiltonCA, CheungMK, OsannK. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol2006;103:679–683.
HamiltonCACheungMKOsannK. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol2006;103:679–683.
)| false
MehtaN, YamadaSD, RotmenschJ, MundtAJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;57:1004–1009.
MehtaNYamadaSDRotmenschJMundtAJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;57:1004–1009.
)| false
MurphyKT, RotmenschJ, YamadaSD, MundtAJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;55:1272–1276.
MurphyKTRotmenschJYamadaSDMundtAJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;55:1272–1276.
)| false
SoodBM, JonesJ, GuptaS. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys2003;57:208–216.
SoodBMJonesJGuptaS. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys2003;57:208–216.
)| false
WolfsonAH, BradyMF, RoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
WolfsonAHBradyMFRoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
)| false
HomesleyHD, FiliaciV, MarkmanM. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol2007;25:526–531.
HomesleyHDFiliaciVMarkmanM. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol2007;25:526–531.
)| false
SuttonG, KaudererJ, CarsonLF. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:630–634.
SuttonGKaudererJCarsonLF. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:630–634.
)| false
ReedNS, MangioniC, MalmströmH. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer2008;44:808–818.
ReedNSMangioniCMalmströmH. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer2008;44:808–818.
)| false
CallisterM, RamondettaLM, JhingranA. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys2004;58:786–796.
CallisterMRamondettaLMJhingranA. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys2004;58:786–796.
)| false
ChiD, MychalczakB, SaigoP. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol1997;65:493–498.
ChiDMychalczakBSaigoP. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol1997;65:493–498.
)| false
KnockeT, WeitmannH, KuceraH. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol1999;73:389–395.
KnockeTWeitmannHKuceraH. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol1999;73:389–395.
)| false
LarsonB, SilfverswardC, NilssonB. Mixed mullerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol1990;17:123–132.
LarsonBSilfverswardCNilssonB. Mixed mullerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol1990;17:123–132.
)| false
DusenberyKE, PotishRA, ArgentaPA, JudsonPL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol2005;28:295–300.
DusenberyKEPotishRAArgentaPAJudsonPL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol2005;28:295–300.
)| false
NemaniD, MitraN, GuoM, LinL. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol2008;111:82–88.
NemaniDMitraNGuoMLinL. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol2008;111:82–88.
)| false
WolfsonAH, BradyMF, RoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
WolfsonAHBradyMFRoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
)| false
PinkD, LindnerT, MrozekA. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol2006;101:464–469.
PinkDLindnerTMrozekA. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol2006;101:464–469.
)| false
ZivanovicO, IasonosA, LeitaoMM. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system [abstract]. J Clin Oncol2008;26:Abstract 5554.
ZivanovicOIasonosALeitaoMM. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system [abstract]. J Clin Oncol2008;26:Abstract 5554.
)| false
GiuntoliRN, MetzingerD, DiMarcoC. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol2003;89:460–469.
GiuntoliRNMetzingerDDiMarcoC. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol2003;89:460–469.
)| false
HensleyML, MakiR, VenkatramanE. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:2824–2831.
HensleyMLMakiRVenkatramanE. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:2824–2831.
)| false
HensleyML, BlessingJA, MannelR, RosePG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol2008;109:329–334.
HensleyMLBlessingJAMannelRRosePG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol2008;109:329–334.
)| false
LookKY, SandlerA, BlessingJA. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol2004;92:644–647.
LookKYSandlerABlessingJA. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol2004;92:644–647.
)| false
JudsonI, RadfordJA, HarrisM. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2001;37:870–877.
JudsonIRadfordJAHarrisM. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2001;37:870–877.
)| false
SuttonG, BlessingJ, HanjaniP. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:749–752.
SuttonGBlessingJHanjaniP. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:749–752.
)| false
GallupDG, BlessingJA, AndersenW. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol2003;89:48–51.
GallupDGBlessingJAAndersenW. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol2003;89:48–51.
)| false